In some embodiments, the invention provides a method for extracting at least 55% of immunoglobulin such as IgG present in a biological fluid from the biological fluid, comprising contacting a biological fluid suspected of containing immunoglobulin with a solid support covalently bonded to a ligand that specifically binds to immunoglobulin under conditions sufficient for non-covalent binding of immunoglobulin to the ligand; and contacting the solid support with an elution solution under condition whereby the non-covalently bound immunoglobulin is released from the ligand and into the elution solution, wherein at least 55% of the IgG present in the biological fluid is extracted into the elution solution. In some embodiments, the invention provides a method for enriching immunoglobulin from a biological fluid comprising obtaining an initial biological fluid suspected of containing immunoglobulin and removing non-immunoglobulin components naturally occurring in the initial biological fluid to obtain a non-immunoglobulin component-reduced biological fluid. The invention further provides a containers, such as a bags and columns, and apheresis systems for performing or use in the methods.

The invention relates to an apparatus for carrying out an extracorporeal blood treatment in which a substitution fluid is administered to the patient, wherein the apparatus comprises an extracorporeal blood circuit and a substitution line opening into the extracorporeal blood circuit, wherein the substitution line has at least one heating container, and wherein a pump is arranged in the substitution line downstream of the heating container or containers for the conveying of substitution fluid into the extracorporeal blood circuit.

A plasmapheresis system and a method for operating a plasmapheresis system are provided by which the reservoir for the concentrated red blood cells (RCC) has a first chamber for receiving anticoagulant used for priming the separator and purging the system of air prior to the initial draw cycle and a second chamber for receiving separated red blood cells. Because the entire volume of second chamber of the RCC reservoir may now receive separated red blood cells and no AC prime volume, a greater amount of whole blood may be processed in the first draw cycle, thus resulting in a greater total volume of Immunoglobulin G (IgG) being collected during the plasmapheresis procedure.

Described are embodiments that include methods and devices for separating components from multi-component fluids. Embodiments may involve use of separation vessels and movement of components into and out of separation vessels through ports. Embodiments may involve the separation of plasma from whole blood. Also described are embodiments that include methods and devices for positioning portions, e.g., loops, of disposables in medical devices. Embodiments may involve use of surfaces for automatically guiding loops to position them into a predetermined position.

A method is provided for controlling fluid flow through a tubing segment is provided in which a pump draws fluid through the tubing segment using negative pressure P. The method includes the steps of: a) operating the pump at an initial commanded fluid flow rate to draw fluid through the tubing segment; b) measuring on a continuous basis the P in the tubing segment; c) determining into which of four zones the measured P falls, a first zone being where P>X.sub.1, a second zone being where X.sub.1>P>X.sub.2, a third zone where X.sub.2>P>X.sub.3, and a fourth zone where X.sub.3>P; d) if P is in the first zone for greater than a first pre-established time period, then increasing the commanded flow rate of the pump and returning to step b); e) if P is in the second zone, then continuing to operate the pump at the flow rate at which the pump is currently operated and returning to step b); f) if P is in the third zone, for greater than a second pre-established time period, then decreasing the commanded flow rate of the pump and returning to step b); and g) if P is in the fourth zone, then commanding the pump to stop. A system including a programmable controller configured to automatically perform the method is also disclosed

A plasmapheresis system and a method for operating a plasmapheresis system are provided by which the volume/weight of anticoagulated plasma that is collected is optimized. In one example, a nomogram is provided that utilizes the donor's hematocrit to calculate the volume/weight of raw plasma within a plasma product having the maximum volume permitted by the FDA nomogram. In a plasmapheresis procedure having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the donor's increasing hematocrit, thus resulting in a greater total volume of plasma product to be collected during the plasmapheresis procedure.

A method for creating a custom cell processing protocol includes providing a cell processing device having a display, a blood component separation device, and a pump. The method may then select, using the display, a first and second processing phase. The first processing phase has a plurality of first processing phase parameters and the second processing phase has a plurality of second processing phase parameters. The method may then modify the first and second processing phase parameters using the display, and create a custom protocol algorithm. The algorithm may be based, at least in part, on the selected first and second processing phases and the modified first and second processing phase parameters

A column for removal of a component from a fluid is disclosed. The column has a compartment with a cross sectional area. The compartment contains beads having a diameter. A ligand selected to bind to the component is coupled to the beads. The cross-sectional area and bead diameter are selected to maintain a flow velocity of the fluid within the compartment below a first threshold, thereby reducing leaching of the ligand into the fluid. Also described herein is an adsorbent comprising a ligand that is attached to a substrate by an amine bond, wherein the ligand is resistant to dissociation from the substrate.

The present invention is related to human platelet lysate or a fraction that is enriched for human platelet lysate derived extracellular vesicles and their use in medicine, particularly for the prevention and/or treatment of inflammatory driven diseases, neurodegenerative diseases, immune/autoimmune diseases, cardiovascular diseases, dermatologic diseases, orthopedic diseases, tissue regenerative medicine, oncologic diseases, infectious diseases, transplant rejections, stroke, ischemia or Graft-versus-Host Disease. The present invention is further related to a method of manufacture of a pharmaceutical preparation or a diagnostic preparation or a cosmetic preparation comprising the step of adding human platelet lysate or a fraction that is enriched for human platelet lysate derived extracellular vesicles to the pharmaceutical preparation or a diagnostic preparation or a cosmetic preparation.

A portable platelet apheresis system can include: a whole blood inlet configured to receive whole blood; an anticoagulant source containing an anticoagulant; a mixer fluidly coupled with the whole blood inlet and anticoagulant source and configured to mix the whole blood and the anticoagulant; a whole blood sorter microfluidic network; a platelet poor outlet positioned to receive a platelet poor fraction; and a platelet concentrator outlet positioned to receive a concentrated platelet fraction. The whole blood sorter microfluidic network includes: a sorter constricted region having a first cross-sectional dimension; a sorter expansion region having a second cross-sectional dimension that is larger than the first cross-sectional dimension; at least one sorter side channel (platelet rich plasma channel) formed into a side of the sorter expansion region; and at least one sorter outlet (platelet poor plasma channel) that is downstream or medial from the at least one sorter side channel.